Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
Status:
Recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
This is the first pilot phase II trial assessing the response of SBRT layered on Darolutamide
(BAY1841788) on RPFS and deferring palliative second line systemic therapy in M0CRPC with
oligoprogression.